Intracerebral Hemorrhage Deferoxamine Trial - iDEF Ttrial
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 294 participants.
Also called NCT02175225
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 294 participants
- Sponsor
- Beth Israel Deaconess Medical Center
- Columbia University
- Duke University
- Hartford Hospital
- Henry Ford Hospital
- Johns Hopkins University
- Loyola University
- Massachusetts General Hospital
- Medical University of South Carolina
- Mount Sinai Hospital, New York
- NYU Langone Health
- National Institute of Neurological Disorders and Stroke
- Ohio State University
- Oregon Health and Science University
- Rhode Island Hospital
- Rush University Medical Center
- Stanford University
- The University of Texas Health Science Center, Houston
- University Hospitals Cleveland Medical Center
- University of Alberta
- University of Calgary
- University of California, San Francisco
- University of Florida
- University of Iowa
- University of Massachusetts, Worcester
- University of Pennsylvania
- University of Washington
- Weill Medical College of Cornell University
- Registry
-
NCT02175225
-
- Other papers using this trial's data
- Deferoxamine mesylate in patients with intracerebral haemorrhage (i-DEF): a multicentre, randomised, placebo-controlled, double-blind phase 2 trial
- Early neurological improvement with deferoxamine after intracerebral hemorrhage: A post hoc analysis of the i-DEF trial
- Effect of Deferoxamine on Trajectory of Recovery After Intracerebral Hemorrhage: A Post Hoc Analysis of the i-DEF Trial
- Evolution of Perihematomal Edema Mean Hounsfield Unit and Its Association with Clinical Outcome in Intracerebral Hemorrhage: A Post Hoc Analysis of the i-DEF Trial
- Hemoglobin and Perihematomal Edema After Intracerebral Hemorrhage: A Post Hoc Analysis of the i-DEF Trial
- The Prognostic Roles of Perihematomal Edema and Ventricular Size in Patients with Intracerebral Hemorrhage
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Canada
- Registry status
- Completed
Technical summary
Registry record NCT02175225. Randomized; quadruple masking; primary purpose treatment. Start 2014-10 (actual); primary completion 2018-02-10 (actual). Results posted on 2019-05-30.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Intracerebral Hemorrhage Deferoxamine Trial - iDEF Ttrial
- Condition
- Intracerebral Hemorrhage
- Intervention (Drug)
- Deferoxamine Mesylate
- Intervention (Drug)
- Placebo (for Deferoxamine Mesylate)
- Lead sponsor
- Beth Israel Deaconess Medical Center
- Collaborator
- Medical University of South Carolina
- Collaborator
- National Institute of Neurological Disorders and Stroke (NINDS)
- Collaborator
- Massachusetts General Hospital
- Collaborator
- University of Massachusetts, Worcester
- Collaborator
- University of Pennsylvania
- Collaborator
- Johns Hopkins University
- Collaborator
- Duke University
- Collaborator
- University of North Carolina
- Collaborator
- University of Florida
- Collaborator
- Henry Ford Hospital
- Collaborator
- Ohio State University
- Collaborator
- St. Joseph's Hospital and Medical Center, Phoenix
- Collaborator
- University of California, San Francisco
- Collaborator
- Oregon Health and Science University
- Collaborator
- Yale New Haven Health System Center for Healthcare Solutions
- Collaborator
- University of Iowa
- Collaborator
- Hartford Hospital
- Collaborator
- The University of Texas Health Science Center, Houston
- Collaborator
- Rhode Island Hospital
- Collaborator
- Stanford University
- Collaborator
- University of Washington
- Collaborator
- University of Calgary
- Collaborator
- Hopital de l'Enfant-Jesus
- Collaborator
- University of Alberta
- Collaborator
- Rush University Medical Center
- Collaborator
- University Hospitals Cleveland Medical Center
- Collaborator
- Columbia University
- Collaborator
- Weill Medical College of Cornell University
- Collaborator
- NYU Langone Health
- Collaborator
- Mount Sinai Hospital, New York
- Collaborator
- Loyola University
Registry records
Assembled by a program from ROR and ClinicalTrials.gov. No person wrote or checked these pages, and they are counted apart from the pages that people wrote. Lists of trials come from the registry's own coding and may miss trials.
Registry organizations 27
-
An organization that ClinicalTrials.gov lists as a sponsor or collaborator of 9 trials in this atlas.
-
An organization that ClinicalTrials.gov lists as a sponsor or collaborator of 17 trials in this atlas.
-
An organization that ClinicalTrials.gov lists as a sponsor or collaborator of 19 trials in this atlas.
-
An organization that ClinicalTrials.gov lists as a sponsor or collaborator of 3 trials in this atlas.
-
An organization that ClinicalTrials.gov lists as a sponsor or collaborator of 3 trials in this atlas.
-
An organization that ClinicalTrials.gov lists as a sponsor or collaborator of 26 trials in this atlas.
-
An organization that ClinicalTrials.gov lists as a sponsor or collaborator of 3 trials in this atlas.
-
An organization that ClinicalTrials.gov lists as a sponsor or collaborator of 36 trials in this atlas.
-
An organization that ClinicalTrials.gov lists as a sponsor or collaborator of 23 trials in this atlas.
-
An organization that ClinicalTrials.gov lists as a sponsor or collaborator of 5 trials in this atlas.
Record details
- Record id
cardio:ct-nct02175225- Content hash
58254cc52d0eeead938d7e641ee541e3e18c755421146f10d3332d0da5aaf03c